{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE347nnn/GSE347086/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347086"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Combined transcriptomic profiling of anti-PD-1 immunotherapy and FGFR inhibitor AZD4547 in a CT26 colorectal cancer syngeneic mouse model","description":"This study investigated the transcriptomic effects of anti-PD-1 immunotherapy combined with the FGFR inhibitor AZD4547 in a CT26 colorectal cancer syngeneic mouse model. BALB/c mice bearing CT26 subcutaneous tumors were randomized into four treatment groups: Rat IgG2a + PBS (control), anti-PD-1 antibody (anti-PD-1), FGFR inhibitor AZD4547 (FGFRi), and AZD4547 plus anti-PD-1 combination (FGFRi+anti-PD-1). Total RNA was extracted from tumor tissues and subjected to paired-end bulk RNA-seq on the Illumina NovaSeq 6000 platform (PE150). Clean reads were aligned to the mouse reference genome GRCm38/mm10, and gene expression was quantified as raw counts and FPKM, followed by differential expression and enrichment analyses.","dates":{"publication":"2026/09/26"},"accession":"GSE347086","cross_references":{"GSM":["GSM10045790","GSM10045792","GSM10045791","GSM10045787","GSM10045786","GSM10045789","GSM10045788","GSM10045783","GSM10045782","GSM10045785","GSM10045784","GSM10045781","GSM10045780","GSM10045776","GSM10045775","GSM10045778","GSM10045777","GSM10045772","GSM10045794","GSM10045793","GSM10045774","GSM10045796","GSM10045795","GSM10045773","GSM10045779"],"GPL":["24247"],"GSE":["347086"],"taxon":["Mus musculus"]}}